ERBB2 and breast cancer: When Her-2 positive breast cancer cells (AU565 and MCF-7) were exposed to EGCG, the inactivation of the PI3K/Akt and MAPK cascade signaling, the suppression of heregulin-b1-induced fatty acid synthase expression, and high caspase-9 activity were observed.